A POWERFUL RESEARCH AND
DEVELOPMENT ENGINE

Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

  • Phase 1 trials Phase 1 trials

    Phase 1 Trials

    CEMIPLIMAB*

    PD-1 Antibody Cancer

    REGN3767

    LAG-3 Antibody Cancer

    REGN1979

    CD20xCD3 Antibody Cancer

    REGN4018*

    MUC16xCD3 Antibody Cancer

    REGN4659

    CTLA4 Antibody Cancer
    REGN5093
    METxMET Antibody Cancer

    REGN5458*

    BCMAxCD3 Antibody Cancer
    REGN5459*
    BCMAxCD3 Antibody Cancer
    REGN5678
    PSMAxCD28 Antibody Cancer

    REGN3048-3051

    Middle East Respiratory Coronavirus Antibody MERS-CoV infection

    REGN4461

    LEPR Antibody Lipodystrophy and obesity
    REGN5713-5714-5715
    Betv1 Antibody Birch Allergy
  • Phase 2 trials Phase 2 trials

    Phase 2 Trials

    AFLIBERCEPT
    VEGF Trap High-dose for wet age-related macular degeneration (AMD)

    CEMIPLIMAB*

    PD-1 Antibody Basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (CSCC)
    REGN1979
    CD20xCD3 Antibody Relapsed/refractory follicular lymphoma

    DUPILUMAB*

    IL-4R Antibody Grass allergy, peanut allergy

    SARILUMAB*

    IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis

    REGN1908-1909

    Fel d 1 Antibody Cat allergy

    REGN3500*

    IL-33 Antibody Asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis

    REGN5069

    GFRα3 Antibody Osteoarthritis knee pain

    GARETOSMAB

    Activin A Antibody Fibrodysplasia Ossificans Progressiva (FOP)

    EVINACUMAB

    ANGPTL-3 Antibody Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia

    POZELIMAB

    C5 Antibody Paroxysmal nocturnal hemoglobinuria
  • Phase 3 trials Phase 3 trials

    Phase 3 Trials

    AFLIBERCEPT
    VEGF Trap Retinopathy of Prematurity (ROP)

    ALIROCUMAB*

    PCSK9 Antibody Homozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia in pediatrics

    CEMIPLIMAB*

    PD-1 Antibody Non-small cell lung cancer (NSCLC), cervical cancer, cutaneous squamous cell carcinoma (CSCC) (adjuvant)

    REGN-EB3

    Ebola Virus Antibody Ebola virus infection

    DUPILUMAB*

    IL-4R Antibody Atopic dermatitis in pediatrics, asthma in pediatric, eosinophilic esophagitis, COPD

    SARILUMAB*

    IL-6R Antibody Polymyalgia rheumatica, giant cell arteritis

    EVINACUMAB

    ANGPTL-3 Antibody Homozygous familial hypercholesterolemia (HoFH)

    FASINUMAB†

    NGF Antibody Chronic pain from osteoarthritis of the knee or hip
  • IMMUNOLOGY & INFLAMMATORY DISEASES
  • ONCOLOGY
  • OPHTHALMOLOGY
  • RARE DISEASES
  • CARDIOVASCULAR/METABOLIC DISEASES
  • INFECTIOUS DISEASES
  • PAIN

Trials Footnotes

* in collaboration with Sanofi

† in collaboration with Teva and Mitsubishi Tanabe

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.